SCHEMBL832934

SCHEMBL832934

O=C(O)CC1CCCc2c1[nH]c1ccccc21

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.60
SIRT2 Q8IXJ6 1/20 0.60
BRD3 Q15059 1/20 0.59
MAPKAPK2 P49137 1/20 0.51
RB1 P06400 4/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
S1PR1 P21453 2/20 0.48
TBXA2R P21731 1/20 0.46
PTGDR Q13258 1/20 0.46
GRIN2B Q13224 1/20 0.46
CDKN1A P38936 1/20 0.45
HTR7 P34969 1/20 0.45
TP53 P04637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11720431 0.96 SIRT1 (0.55) SIRT1SIRT2BRD3MAPKAPK2RB1
SCHEMBL29141422 0.92 SIRT1 (0.58) SIRT1SIRT2BRD3MAPKAPK2MEN1
SCHEMBL30762333 0.92 SIRT1 (0.58) SIRT1SIRT2BRD3MAPKAPK2MEN1
SCHEMBL11729530 0.92 SIRT1 (0.58) SIRT1SIRT2BRD3MAPKAPK2MEN1
SCHEMBL9459050 0.83 SIRT1 (0.62) SIRT1MAPKAPK2S1PR1CDKN1A
SCHEMBL12923704 0.83 SIRT1 (0.53) SIRT1SIRT2BRD3RB1MEN1
SCHEMBL9019672 0.82 BRD3 (0.60) BRD3MAPKAPK2S1PR1TBXA2R
SCHEMBL6924595 0.81 GRIN2B (0.59) SIRT1SIRT2BRD3MAPKAPK2RB1
SCHEMBL13751063 0.80 BRD3 (0.61) SIRT1SIRT2BRD3RB1MEN1
SCHEMBL2143575 0.79 SIRT1 (0.77) SIRT1SIRT2BRD3MAPKAPK2RB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298622-A1 APPARATUSES AND TECHNIQUES FOR BIOACTIVE DRUG DELIVERY IN THE PROSTATE GLAND VANCE WASEET 2010-11-25 US claimed
US-20070225544-A1 APPARATUSES AND TECHNIQUES FOR BIOACTIVE DRUG DELIVERY IN THE PROSTATE GLAND VANCE WASEET 2007-09-27 US claimed
WO-2007098443-A2 APPARATUSES AND TECHNIQUES FOR BIOACTIVE DRUG DELIVERY IN THE PROSTATE GLAND VANCE WASEET (US) 2007-08-30 WO claimed
JP-61249962-A None JP disclosed
EP-2558447-B1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2014-09-17 EP disclosed
US-8697869-B2 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2014-04-15 US disclosed
US-20130065902-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-03-14 US disclosed
EP-2558447-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-02-20 EP disclosed
US-8143304-B2 (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2012-03-27 US disclosed
EP-2051962-B1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-26 EP disclosed
WO-2011117798-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2011-09-29 WO disclosed
US-4616028-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-10-07 US disclosed
US-4584312-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-04-22 US disclosed
US-4584312-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-04-22 US disclosed
US-4584312-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-04-22 US disclosed
US-4578398-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-03-25 US disclosed
US-4578398-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-03-25 US disclosed
US-4578398-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1986-03-25 US disclosed
US-4057559-A ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1977-11-08 US disclosed
US-4057559-A ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1977-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065902-A1 3-(HETEROARYL-AMINO)-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGDR, PTGER1, PTGDR2 SIRT1 2267/4885SIRT2 1831/4885BRD3 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.